Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy.
BACKGROUND
Cirrhosis is a diffuse process of hepatic fibrosis and regenerative nodule formation of unknown pathogenesis. Transforming growth factor (TGF) beta 1 induces the production of extracellular matrix proteins by liver cells and has been implicated in the pathogenesis of hepatic fibrosis in laboratory animals. TGF alpha is a hepatocyte mitogen that participates in liver regeneration.


METHODS
Using Northern blot analysis, we studied the expression of TGF beta 1 messenger RNA (mRNA) in liver specimens from 42 patients with chronic hepatitis and cirrhosis and 12 subjects with either normal or fatty livers. The results were correlated with measurements of procollagen Type I mRNA in liver tissue, procollagen Type III peptide in serum, and the degree of histologic injury. We also investigated whether TGF alpha mRNA would be detectable in biopsy specimens of livers with proliferative activity.


RESULTS
TGF beta 1 mRNA expression correlated closely with the expression of procollagen Type I mRNA (r = 0.94) and serum procollagen Type III peptide (r = 0.89) and with the histologic activity index (r = 0.73). All patients with increased fibrogenic activity (serum procollagen Type III peptide level, greater than 11.9 micrograms per liter) had increased levels of TGF beta 1 mRNA (2 to 14 times the levels in the control group or in patients with normal fibrogenic activity), and both TGF alpha and H3 histone (a marker of DNA synthesis) mRNAs were detectable in patients with regenerative nodules. Six of eight patients with hepatitis C treated with interferon alfa for one year had sustained clinical responses with normalization of serum procollagen Type III peptide and aminotransferase activity. All these patients had normal levels of TGF beta 1 mRNA in liver specimens obtained at the end of the year.


CONCLUSIONS
TGF beta 1 may have an important role in the pathogenesis of fibrosis in patients with chronic liver disease, and TGF alpha expression may be associated with liver regeneration in these patients.
Castilla
A
A
Department of Internal Medicine, University of Navarra, Pamplona, Spain.
Prieto
J
J
Fausto
N
N
D000328:Adult; D015152:Blotting, Northern; D016326:Extracellular Matrix Proteins / Q000096:biosynthesis; D005234:Fatty Liver / Q000150:complications; D005260:Female; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases / Q000378:metabolism; D006509:Hepatitis B / Q000473:pathology / Q000628:therapy; D006526:Hepatitis C / Q000473:pathology / Q000628:therapy; D006657:Histones / Q000096:biosynthesis; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D008099:Liver / Q000378:metabolism; D008103:Liver Cirrhosis / Q000378:metabolism / Q000473:pathology* / Q000628:therapy; D008115:Liver Regeneration / Q000502:physiology; D008297:Male; D008875:Middle Aged; D011347:Procollagen / Q000378:metabolism; D012333:RNA, Messenger / Q000235:genetics; D016211:Transforming Growth Factor alpha / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology*; D016212:Transforming Growth Factor beta / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology*
D016326:Extracellular Matrix Proteins; D006657:Histones; D007370:Interferon Type I; D011347:Procollagen; D012333:RNA, Messenger; D016211:Transforming Growth Factor alpha; D016212:Transforming Growth Factor beta; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases